The week in pharma: action, reaction and insight – week to October 21, 2022
By Barbara Obstoj-Cardwell. Editor
Licensing and M&A deals featured in last week’s news. First up, MacroGenics signed a collaboration with US biotech major Gilead Sciences last Monday relating to its antibody MGD024 for indications including myeloid leukemia that could earn the company as much as $1.7 billion. Jazz Pharmaceuticals entered a deal with Zymeworks that could cost it over $1.7 billion for rights to the latter’s zanidatamab, an HER2-targeting antibody. Swiss pharma giant Roche signed a license agreement with Austria’s Hookipa Pharma for HB-7001, an arenaviral immunotherapy for KRAS-mutated cancers. Also, Eli Lilly on Tuesday announced it is acquiring US precision medicines company Akouos for up to $610 million, along with its hearing loss treatment candidate AK-OTOF. And AbbVie announced an agreement to acquire UK biotech DJS Antibodies for around $255 million
MacroGenics MGD024 deal provides important cash infusion
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze